Literature DB >> 16960939

High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis.

David Launay1, Martine Remy-Jardin, Ulrique Michon-Pasturel, Ioana Mastora, Eric Hachulla, Marc Lambert, Valerie Delannoy, Viviane Queyrel, Alain Duhamel, Regis Matran, Pascal De Groote, Pierre-Yves Hatron.   

Abstract

OBJECTIVE: To investigate the use of high resolution computed tomography (HRCT) in diagnosis of patients with fibrosing alveolitis associated with systemic sclerosis (FA-SSc), and to determine predictors of disease progression.
METHODS: We retrospectively studied 90 patients with SSc who had undergone an initial (Time 1) and followup (Time 2) clinical and HRCT evaluation, with a mean +/- SD interval of 5.14 +/- 2.98 years between T1 and T2.
RESULTS: At T1, HRCT was normal in 40 patients; at T2, 34/40 (85%) continued to have a normal HRCT. For the 50 patients with FA-SSc on HRCT scan at T1, the overall disease progression comprised extension of lung changes toward the apices with worsening of lung fibrosis at T2. Among the 37 patients who had areas of isolated ground-glass opacities at T1, 25 (68%) had progression of lung fibrosis at T2. These 25 patients were mostly men, who showed a more marked decrease of diffusing capacity and a longer interval between T1 and T2.
CONCLUSION: The results emphasize the good longterm prognosis indicated by a normal initial HRCT in SSc. Patients with FA-SSc with abnormal HRCT experienced progressive replacement of ground-glass opacities by honeycombing and/or traction bronchiectasis/bronchiolectasis. Ground-glass opacity is probably the first step of lung fibrosis in SSc, and treatment should be discussed even at this early stage.

Entities:  

Mesh:

Year:  2006        PMID: 16960939

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  44 in total

Review 1.  Interstitial lung disease in scleroderma.

Authors:  Sara R Schoenfeld; Flavia V Castelino
Journal:  Rheum Dis Clin North Am       Date:  2015-02-26       Impact factor: 2.670

Review 2.  Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases.

Authors:  Aryeh Fischer; Jörg Distler
Journal:  Clin Rheumatol       Date:  2019-08-19       Impact factor: 2.980

Review 3.  Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Ivan O Rosas; Paul F Dellaripa; David J Lederer; Dinesh Khanna; Lisa R Young; Fernando J Martinez
Journal:  Ann Am Thorac Soc       Date:  2014-04

4.  Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.

Authors:  Vivek Nagaraja; Marco Matucci-Cerinic; Daniel E Furst; Masataka Kuwana; Yannick Allanore; Christopher P Denton; Ganesh Raghu; Vallerie Mclaughlin; Panduranga S Rao; James R Seibold; John D Pauling; Michael L Whitfield; Dinesh Khanna
Journal:  Arthritis Rheumatol       Date:  2020-05-18       Impact factor: 10.995

Review 5.  Subclinical interstitial lung disease: why you should care.

Authors:  Tracy J Doyle; Gary M Hunninghake; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2012-02-23       Impact factor: 21.405

Review 6.  Systemic sclerosis--challenges for clinical practice.

Authors:  Zsuzsanna H McMahan; Laura K Hummers
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

Review 7.  Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.

Authors:  Elizabeth R Volkmann; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2016-11

8.  Utility of pulmonary ultrasound to identify interstitial lung disease in patients with rheumatoid arthritis.

Authors:  Natalia Mena-Vázquez; Francisco Gabriel Jimenez-Núñez; Francisco Javier Godoy-Navarrete; Sara Manrique-Arija; María Carmen Aguilar-Hurtado; Carmen María Romero-Barco; Inmaculada Ureña-Garnica; F Espildora; María Isabel Padin-Martín; Antonio Fernández-Nebro
Journal:  Clin Rheumatol       Date:  2021-02-21       Impact factor: 2.980

Review 9.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

Review 10.  Imaging lung disease in systemic sclerosis.

Authors:  Diane Strollo; Jonathan Goldin
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.